Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGT1 | P19440 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 4/20 | 0.43 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23286133 | 0.89 | SMN1; SMN2 (0.46) | SMN1; SMN2SIRT5 | |
| SCHEMBL16450329 | 0.89 | SMN1; SMN2 (0.46) | SMN1; SMN2SIRT5 | |
| SCHEMBL29071221 | 0.82 | SPHK1 (0.37) | MMP2 | |
| SCHEMBL22264483 | 0.82 | SIRT1 (0.41) | SMN1; SMN2MMP2SIRT5 | |
| SCHEMBL17803625 | 0.82 | SIRT1 (0.41) | SMN1; SMN2MMP2SIRT5 | |
| SCHEMBL23680474 | 0.81 | ATM (0.48) | SIRT5 | |
| SCHEMBL25932816 | 0.80 | SIRT5 (0.62) | SIRT5PRSS1PRSS2PRSS3 | |
| SCHEMBL30527290 | 0.80 | SIRT5 (0.62) | SIRT5PRSS1PRSS2PRSS3 | |
| SCHEMBL24475446 | 0.79 | SPHK1 (0.49) | MMP2KLKB1PRSS1 | |
| SCHEMBL27431579 | 0.79 | SPHK1 (0.49) | MMP2KLKB1PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210230218-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | MABPLEX INTERNATIONAL, LTD. (CN) | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230218-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | VIP, DNPEP, PREP | GGT1 2409/4885SMN1; SMN2 1997/4885MMP2 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.